Gradient Tumor Microenvironment-Promoted Penetrating Micelles for Hypoxia Relief and Immunosuppression Reversion in Pancreatic Cancer Treatment.

[1]  R. Bartrons,et al.  BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy , 2022, Nature Communications.

[2]  S. Karam,et al.  Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors , 2022, Nature Communications.

[3]  Huile Gao,et al.  Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy , 2022, Acta pharmaceutica Sinica. B.

[4]  N. Schultz,et al.  BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling , 2022, Nature Communications.

[5]  Guofeng Li,et al.  Dual‐Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor‐Resident Intracellular Bacteria , 2022, Advanced materials.

[6]  J. Freeman,et al.  Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching , 2022, Cell Death & Disease.

[7]  Huamin Wang,et al.  Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ , 2022, Nature Communications.

[8]  Jun Ma,et al.  Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature , 2022, Cancer medicine.

[9]  Chen Jiang,et al.  A neutrophil-biomimic platform for eradicating metastatic breast cancer stem-like cells by redox microenvironment modulation and hypoxia-triggered differentiation therapy , 2022, Acta pharmaceutica Sinica. B.

[10]  C. Li,et al.  Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer. , 2022, Biomaterials.

[11]  D. Hayes,et al.  The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF‐β receptor plus dual checkpoint inhibition maintains antitumor immune cells , 2022, Molecular carcinogenesis.

[12]  Chen Jiang,et al.  Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. , 2022, Small.

[13]  B. Kuster,et al.  Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment , 2021, Nature Cancer.

[14]  Minghui Wang,et al.  Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities , 2021, Nature Communications.

[15]  Michael H. Durham,et al.  Probing Multicellular Tissue Fusion of Cocultured Spheroids—A 3D‐Bioassembly Model , 2021, Advanced science.

[16]  E. O’Reilly,et al.  Pancreatic Cancer: A Review. , 2021, JAMA.

[17]  Zhaoming Li,et al.  Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate , 2021, Scientific Reports.

[18]  Mingyuan Gao,et al.  A Cyclodextrin‐Hosted Ir(III) Complex for Ratiometric Mapping of Tumor Hypoxia In Vivo , 2021, Advanced science.

[19]  Guofeng Zhang,et al.  Oxygen‐Evolving Manganese Ferrite Nanovesicles for Hypoxia‐Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy , 2021, Advanced Functional Materials.

[20]  Huile Gao,et al.  The progress and perspective of strategies to improve tumor penetration of nanomedicines , 2020 .

[21]  Karin Wang,et al.  Fibronectin in development and wound healing. , 2020, Advanced drug delivery reviews.

[22]  Z. Dai,et al.  Perfluorocarbon@Porphyrin Nanoparticles for Tumor Hypoxia Relief to Enhance Photodynamic Therapy against Liver Metastasis of Colon Cancer. , 2020, ACS nano.

[23]  T. Efferth,et al.  Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[24]  T. Gress,et al.  Microenvironmental Determinants of Pancreatic Cancer. , 2020, Physiological reviews.

[25]  D. Peer,et al.  Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. , 2019, Biomaterials.

[26]  Jianhua Zhang,et al.  Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-induced Chemotherapy Resistance: Combination of Optimizing Size and Self-inducing High Level of Reactive Oxygen Species. , 2019, ACS applied materials & interfaces.

[27]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[28]  Johannes A Eble,et al.  The extracellular matrix in tumor progression and metastasis , 2019, Clinical & Experimental Metastasis.

[29]  C. Li,et al.  Microthrombus‐Targeting Micelles for Neurovascular Remodeling and Enhanced Microcirculatory Perfusion in Acute Ischemic Stroke , 2019, Advanced materials.

[30]  P. Radhakrishnan,et al.  Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis , 2019, Molecular Cancer.

[31]  Shun Lu,et al.  Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes , 2018, Oncogene.

[32]  M. Najafi,et al.  Tumor microenvironment: Interactions and therapy , 2018, Journal of cellular physiology.

[33]  M. Smit,et al.  Biogenesis and function of extracellular vesicles in cancer. , 2018, Pharmacology & therapeutics.

[34]  K. Miyazono,et al.  Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells , 2018, Oncogene.

[35]  Hongxu Lu,et al.  Multicellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of Nanoparticles. , 2018, Small.

[36]  Bruno Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[37]  W. Hennink,et al.  Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[38]  C. Iacobuzio-Donahue,et al.  Pancreatic cancer biology and genetics from an evolutionary perspective , 2016, Nature Reviews Cancer.

[39]  A. Maitra,et al.  Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer , 2016, British Journal of Cancer.

[40]  A. Theocharis,et al.  Extracellular matrix structure. , 2016, Advanced drug delivery reviews.

[41]  Wenwei Chen,et al.  Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. , 2015, Gene.

[42]  D. Gabrilovich,et al.  Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment , 2014, Immunology.

[43]  D. V. Von Hoff,et al.  Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer , 2014, Expert review of gastroenterology & hepatology.

[44]  A. Whetton,et al.  The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. , 2014, Cancer treatment reviews.

[45]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[46]  M. Wirth,et al.  Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[47]  M. Wirth,et al.  UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy. , 2013, International journal of pharmaceutics.